Curevo, a Seattle-based biotech startup developing a vaccine against shingles, raised $110 million in a Series B round. The fresh cash will help Curevo advance Phase 2 trials of amezosvatein, its ...

Curevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former executive from the UK big pharma to advance its candidate amezosvatein. The ...

Moncef Slaoui, who ran the Operation Warp Speed Covid vaccine effort, is becoming chair of Curevo, a company developing a new shingles vaccine ...

Former Chair of GSK’s vaccine business and Chief Scientific Advisor to Operation Warp Speed, Moncef Slaoui, to join Curevo as Board Chair SEATTLE, March 17, 2025 (GLOBE NEWSWIRE) -- Curevo ...

In its effort to rival GSK’s shingles vaccine Shingrix, Curevo Vaccine has circled up $110 million and recruited two former GSK leaders to its board. The biotech’s series B was led by new ...

The “What It Is (Block Boy)” hitmaker opened up to PEOPLE about the upcoming arena tour and album following her performance at Cuervo's Cristalino Nights party Brenton Blanchet is a writer ...

Curevo, a Seattle-based biotech startup developing a vaccine against shingles, raised $110 million in a Series B round. The fresh cash will help Curevo advance Phase 2 trials of amezosvatein ...

Curevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former executive from the UK big pharma to advance its candidate amezosvatein.

“This Series B round will fund the extension of our successful Phase 2 program into an additional 640 participants, including the key population of adults over age 70, to finalize dose selection ahead ...

SEATTLE, March 17, 2025 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with ...